États financiers détaillés de Intensity Therapeutics, Inc. (INTS): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.
Résumé de l'Analyse
Marges des 12 derniers mois: marge brute 0.0%, marge opérationnelle 0.0%, marge nette 0.0%.
Au prix actuel de $3.81, INTS affiche des résultats négatifs (PER non significatif) et un ROE de -97.73%. La capitalisation boursière s'établit à $10M.
Compte de Résultat (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Revenus | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coût des Ventes | 0 | 0 | 0 | 0 | $147000 | 0 | $26000 |
| Marge Brute | 0 | 0 | 0 | 0 | -$147000 | 0 | -$26000 |
| R&D | $4.4M | $5.1M | $5.9M | $5.1M | $4.8M | $10.5M | $6.8M |
| Frais Généraux | $1.2M | $1.2M | $2.1M | $2.4M | $3.4M | $6.1M | $5.2M |
| Charges Opérationnelles | $5.7M | $6.2M | $8.0M | $7.5M | $8.2M | $16.6M | $12.0M |
| Résultat Opérationnel | -$5.7M | -$6.2M | -$8.0M | -$7.5M | -$8.3M | -$16.6M | -$12.0M |
| EBITDA | -$5.2M | -$6.0M | -$7.9M | -$7.3M | -$10.1M | -$16.3M | -$11.6M |
| Charges d'Intérêt | 0 | 0 | $16767 | $81781 | $305000 | 0 | 0 |
| Résultat Avant Impôts | -$5.4M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| Impôts | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | -$5.2M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| BPA | $-39.50 | $-44.25 | $-58.00 | $-55.50 | $-34.50 | $-29.25 | $-8.56 |
| BPA Dilué | $-39.50 | $-44.25 | $-58.00 | $-55.50 | $-34.50 | $-29.25 | $-8.56 |
| Actions en Circulation (Diluées) | $136120 | $136381 | $136404 | $136404 | $344653 | $556279 | $13.6M |
Compte de Résultat (Trimestriel)
| Année | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Revenus | 0 | 0 | 0 | 0 |
| Marge Brute | 0 | 0 | -$7000 | -$7000 |
| Résultat Opérationnel | -$2.7M | -$3.1M | -$2.5M | -$3.1M |
| EBITDA | $62000 | -$3.0M | -$2.4M | -$3.1M |
| Résultat Net | -$2.7M | -$3.1M | -$2.4M | -$3.0M |
| BPA | $-1.55 | $-1.21 | $-0.96 | $-1.11 |
| BPA Dilué | $-1.55 | $-1.21 | $-0.96 | $-1.11 |
Bilan (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Trésorerie | $3.8M | $9.3M | $4.5M | $1.3M | $8.6M | $2.6M | $11.9M |
| Placements à Court Terme | $4.6M | 0 | 0 | 0 | $6.2M | 0 | 0 |
| Créances | $33634 | $48521 | $51262 | $62304 | 0 | 0 | 0 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $8.6M | $9.5M | $4.7M | $1.5M | $15.5M | $3.4M | $12.7M |
| Immobilisations Corporelles | $252668 | $490240 | $318126 | $139000 | $147000 | $122000 | $96000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $9.0M | $10.1M | $5.2M | $1.8M | $17.3M | $4.8M | $14.1M |
| Dettes Fournisseurs | $393963 | $222707 | $172508 | $603000 | $3.0M | $1.2M | $583000 |
| Dette à Court Terme | $117194 | 0 | $2.0M | $4.3M | 0 | 0 | 0 |
| Passifs Courants | $1.1M | $1.3M | $3.7M | $6.8M | $4.0M | $1.8M | $2.1M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | $79000 |
| Passifs Totaux | $1.3M | $11.7M | $13.9M | $16.9M | $4.1M | $1.9M | $2.2M |
| Réserves | 0 | -$23.2M | -$31.1M | -$38.7M | -$50.5M | -$66.8M | -$78.4M |
| Capitaux Propres | $7.7M | -$1.6M | -$8.7M | -$15.1M | $13.2M | $2.9M | $11.9M |
| Dette Totale | $260270 | $497481 | $2.3M | $4.5M | $158000 | $138000 | $110000 |
| Dette Nette | -$8.1M | -$8.8M | -$2.2M | $3.2M | -$14.6M | -$2.5M | -$11.8M |
| Fonds de Roulement | $7.5M | $8.1M | $1.0M | -$5.4M | $11.5M | $1.6M | $10.6M |
Bilan (Trimestriel)
| Année | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Trésorerie | $7.1M | $11.9M | $10.2M | $9.5M |
| Actifs Totaux | $9.6M | $14.1M | $12.3M | $11.5M |
| Passifs Totaux | $2.4M | $2.2M | $2.3M | $2.3M |
| Capitaux Propres | $7.2M | $11.9M | $10.0M | $9.2M |
| Dette Totale | $118000 | $110000 | $102000 | $95000 |
Tableau de Flux (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Résultat Net | -$5.4M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| Amortissements | 0 | 0 | 0 | $179037 | 0 | 0 | 0 |
| Stock-based Compensation | $561377 | $555488 | $719822 | $1.2M | $1.4M | $3.1M | $2.0M |
| Variation du BFR | $306908 | -$12033 | $176801 | $756689 | -$633000 | -$2.1M | $347000 |
| Cash Flow Opérationnel | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M |
| CapEx | 0 | 0 | $3 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rachat d'Actions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendes Payés | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M |
Tableau de Flux (Trimestriel)
| Année | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Cash Flow Opérationnel | -$2.4M | -$2.4M | -$1.8M | -$2.3M |
| CapEx | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$2.4M | -$2.4M | -$1.8M | -$2.3M |
| Dividendes Payés | 0 | 0 | 0 | 0 |
| Stock-based Compensation | 0 | $450000 | $387000 | $387000 |
Croissance et Marges (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Croissance Résultat Net (annuelle) | | -13.9% | -32.6% | +4.0% | -39.0% | -54.4% | +28.7% |
| Croissance BPA (annuelle) | | -12.0% | -31.1% | +4.3% | +37.8% | +15.2% | +70.7% |
| Variation Actions (annuelle) | | +0.2% | +0.0% | +0.0% | +152.7% | +61.4% | +2338.3% |
| Croissance FCF (annuelle) | | -21.6% | -27.1% | +19.8% | -31.5% | -111.2% | +39.3% |
| Taux d'Imposition Effectif | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Données par Action (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF par Action | $-32.44 | $-39.38 | $-50.05 | $-40.16 | $-20.91 | $-27.36 | $-0.68 |
| Dividende par Action | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Actions en Circulation (Basiques) | $136080 | $136360 | $136400 | $136400 | $306160 | $556240 | $13.6M |
Quoi regarder en Biotech
La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.
- Cash Runway — Mois de cash au rythme actuel. <18 mois = risque de dilution urgente
- Cash burn annuel — Rythme de consommation de cash opérationnel. À comparer à la position de cash
- Total Debt — Biotech sans revenus + dette = recette de faillite
- R&D / Capitalisation — Combien ils investissent dans le pipeline vs la valeur de l'entreprise — intensité R&D
- Capitalisation / Cash — S'il cote près de son cash, le marché donne ~0 valeur au pipeline — opportunité ou piège
Rentabilité
| Rentabilité des capitaux propres | -97.73% |
| Rentabilité du capital investi | -99.88% |
| Rentabilité des actifs | -82.31% |
| Marge brute | 0.00% |
| Marge opérationnelle | 0.00% |
| Marge nette | 0.00% |
Santé financière
| Dette / Capitaux propres | 0.01 |
| Ratio de liquidité | 5.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 27.84 |
Ratios Clés (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| PER | -3.77 | -3.37 | -2.57 | -2.68 | -6.21 | -1.50 | -1.20 |
| P/B | 2.63 | -13.04 | -2.34 | -1.35 | 4.98 | 8.39 | 11.72 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Marge Brute | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Marge Opérationnelle | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Marge Nette | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |